MENLO PARK, Calif., Feb. 3, 2011 /PRNewswire/ — Corium
International, Inc., a privately-held advanced transdermal drug
delivery company, today announced the appointment of Dr. Bhaskar
Chaudhuri and David L. Greenwood to the Board of Directors.
Dr. Chaudhuri most recently served as President of Valeant
Pharmaceuticals International and previously was President and
Chief Executive Officer of Dow Pharmaceutical Services, Inc.
Mr. Greenwood is Executive Vice President and Chief Financial
Officer of Geron Corporation.
“We are excited and honored to welcome two executives of Bhaskar
and David’s caliber to Corium’s Board of Directors,” said Peter
Staple, Corium’s President and Chief Executive Officer. “They
bring a breadth of experience and accomplishments that will be
invaluable as Corium advances through its next stages of
growth.”With well over 20 years of industry management experience,
Dr. Chaudhuri brings extensive product development and
commercialization knowledge to Corium. Before joining Dow, he
served as Vice President of R&D at Penederm, Inc., as General
Manager of the Dermatology Division of Mylan Laboratories, and as
Executive Vice President of Scientific Affairs at Bertek
Pharmaceuticals, a subsidiary of Mylan, where he was responsible
for research and development activities as well as certain of the
company’s manufacturing operations. As Chief Executive
Officer of Dow, Dr. Chaudhuri led the company through a transition
from a contract development focus to developing an attractive
internal product pipeline and the company’s eventual merger with
Valeant. Dr. Chaudhuri holds a Doctorate in Physical
Pharmacy, a Master’s of Science in Industrial Pharmacy and a
Bachelor’s of Science in Pharmacy.
Mr. Greenwood brings substantial expertise in financing
pharmaceutical and biotechnology companies. Before joining Geron,
he held various positions in the investment banking field for over
15 years, includi